Deficiency of Soluble α-Klotho as an Independent Cause of Uremic Cardiomyopathy

J. Xie, Y. L. Wu, C. L. Huang

研究成果: 書貢獻/報告類型會議貢獻

8 引文 斯高帕斯(Scopus)

摘要

Cardiovascular disease (CVD) is the major cause of mortality for patients with chronic kidney disease (CKD). Cardiac hypertrophy, occurring in up to 95% patients with CKD (also known as uremic cardiomyopathy), increases their risk for cardiovascular death. Many CKD-specific risk factors of uremic cardiomyopathy have been recognized, such as secondary hyperparathyroidism, indoxyl sulfate (IS)/p-cresyl, and vitamin D deficiency. However, several randomized controlled trials have recently shown that these risk factors have little impact on the mortality of CVD. Klotho is a type 1 membrane protein predominantly produced in the kidney, and CKD is known to be a Klotho-deficient state. Because of its important role in FGF23 and phosphate metabolism, Klotho is believed to affect cardiac growth and function indirectly through FGF23 and phosphate. Recent studies showed that soluble Klotho protects the heart against stress-induced cardiac hypertrophy by inhibiting TRPC6 channel-mediated abnormal Ca2+ signaling in the heart, and the decreased level of circulating soluble Klotho in CKD is an important cause of uremic cardiomyopathy independent of FGF23 and phosphate. These new evidence suggested that Klotho is an independent contributing factor for uremic cardiomyopathy and a possible new target for treatment of this disease.

原文英語
主出版物標題Klotho, 2016
編輯Gerald Litwack
發行者Academic Press Inc.
頁面311-330
頁數20
ISBN(列印)9780128048191
DOIs
出版狀態已發佈 - 2016

出版系列

名字Vitamins and Hormones
101
ISSN(列印)0083-6729

ASJC Scopus subject areas

  • 生理學
  • 內分泌

指紋

深入研究「Deficiency of Soluble α-Klotho as an Independent Cause of Uremic Cardiomyopathy」主題。共同形成了獨特的指紋。

引用此